Cadonilimab Injection

125 mg (10 mL)/vial

This product is administered by intravenous infusion, with a recommended dose of 6 mg/kg, once every 2 weeks, until disease progression or intolerable toxicity occurs.Atypical efficacy responses may be observed (e.g., temporary tumor enlargement or new lesions in the first few months of treatment, followed by tumor shrinkage); if the patient’s clinical symptoms are stable or continue to improve, even if there is initial evidence of disease progression on imaging, based on the judgment of overall clinical benefit, continued use of this product can be considered until disease progression is confirmed.Depending on the safety and tolerability of individual patients, it may be necessary to suspend or permanently discontinue the drug. Increasing or decreasing the dose is not recommended.

This package insert describes the approximate incidence of adverse reactions that may be associated with cadunolimab that were observed in clinical trials. Because clinical trials are conducted in different patient populations and under a variety of different conditions, the incidence of adverse reactions observed in different clinical trials cannot be directly compared and may not reflect the actual incidence in clinical practice.